Astellas Acquisition Bid For OSI Rejected By Board Of U.S.-Based Firm
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma's bid to buy U.S.-based OSI Pharmaceuticals for $3.5 billion was rejected by OSI's board just days after the U.S. company's shareholders filed a court suit to keep the OSI board from blocking the acquisition